Federal Register / Vol. 86, No. 131 / Tuesday, July 13, 2021 / Notices 36757 

substantially benefit rural or 

underserved populations, or help meet 

public health nursing needs in state or 

local health departments; special 

consideration is given to an eligible 

entity that agrees to extend the award to 

train advanced education nurses who 

will practice in designated health 

professional shortage areas. 

The ANE Program Specific Form will 

allow HRSA to effectively target funding 

and measure the impact of the ANE 

programs in meeting the legislative 

intent and program goals of supporting 

the enhancement of advanced nursing 

education and creating opportunities for 

individuals in advanced nursing 

education programs to increase the 

number of advanced practice nurses, 

especially in rural and underserved 

areas. The proposed updates to this 

information collection will assist HRSA 

in: streamlining the application 

submission process across programs; 

enabling an efficient award 

determination process; and facilitating 

HRSA’s ability to monitor the use of 

funds and analyze program outcomes. 

Additionally, collecting this data assists 

HRSA in carrying out the most 

impactful program and ensuring 

resources are used responsibly. 

More specifically, the changes include 

the following: 

• Form name change from ANEW to 

ANE Program Specific Form. 

• Additional instructions for 

applicants are provided in each funding 

opportunity. 

• Modifications to both Table #1 and 

Table #2: 

Æ Revision to instructions to 

incorporate elements for added 

programs. Instructions about completion 

of each table are included within the 

electronic application materials. 

Æ Table titles are rephrased for 

clarity. 

Æ New ‘‘Additional Specialty’’ 

column is created to yield a flexible data 

collection option. 

• Table #1 rows are numbered for 

clarity and more rows are added to: 

Æ Capture auto-tabulation, and 

Æ Reformat/separate Statutory 

Funding Preference data from Special 

Consideration data. 

• Table #2 has: 

o ‘‘Students’’ reworded to 

‘‘participants/trainees’’; 

Æ One column labeled, ‘‘Budget 

Year,’’ to identify the project budget 

year; 

Æ One column to create a space for 

entering the sum for each row; 

Æ Rows to more clearly indicate the 

budget year for up to five years; and, 

Æ One final row to create a space for 

entering the total for each column. 

• Frequency of data collection: Data 

is collected (through the two tables) 

once during the application period for 

each funding announcement. 

• Information determines: 

Æ If applicants meet the funding 

preference or special consideration for 

funding; and 

Æ Projected target and baseline 

numbers of trainees/participants to be 

supported throughout the project 

period. 

Likely Respondents: Likely 

respondents will be current ANE 

Programs awardees and new applicants 

to the ANE Programs. 

Burden Statement: Burden in this 

context means the time expended by 

persons to generate, maintain, retain, 

disclose or provide the information 

requested. This includes the time 

needed to review instructions; to 

develop, acquire, install and utilize 

technology and systems for the purpose 

of collecting, validating and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information; to search 

data sources; to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. The total annual burden 

hours estimated for this ICR are 

summarized in the table below. 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name 

(includes the ANE program specific tables 

and attachments 

Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

ANEW .................................................................................. 236 1 236 7 1,652 

NAT ...................................................................................... 115 1 115 7 805 

ANE–NPR ............................................................................ 101 1 101 7 707 

ANE–NPRIP ......................................................................... 15 1 15 7 105 

ANE–SANE .......................................................................... 54 1 54 7 378 

Total .............................................................................. 521 ........................ 521 ........................ 3,647 

HRSA specifically requests comments 

on (1) the necessity and utility of the 

proposed information collection for the 

proper performance of the agency’s 

functions, (2) the accuracy of the 

estimated burden, (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and (4) the 

use of automated collection techniques 

or other forms of information 

technology to minimize the information 

collection burden. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2021–14804 Filed 7–12–21; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Peter Soukas, J.D., 301–496–2644; 

peter.soukas@nih.gov. Licensing 

information and copies of the patent 

applications listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office, National Institute of 

Allergy and Infectious Diseases, 5601 

Fishers Lane, Rockville, MD 20852; tel. 

301–496–2644. A signed Confidential 


jbell on DSKJLSW7X2PROD with NOTICES
36758 Federal Register / Vol. 86, No. 131 / Tuesday, July 13, 2021 / Notices 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Mononegavirales Vectors Expressing 

Chimeric Antigens 

Description of Technology 

Human respiratory syncytial virus 

(RSV) continues to be the leading viral 

cause of severe acute lower respiratory 

tract disease in infants and children 

worldwide, and also is an important 

cause of morbidity and mortality in the 

elderly. A licensed vaccine or antiviral 

drug suitable for routine use remains 

unavailable. This invention relates to 

the use of murine pneumonia virus 

(MPV—previously known as pneumonia 

virus of mice, PVM—of family 

Pneumoviridae) as a vaccine vector 

expressing the RSV fusion protein F, the 

most important protective antigen of 

RSV. MPV is not a human pathogen and 

is not restricted by immunity to 

common human viruses. MPV replicates 

in the superficial epithelial cells of the 

respiratory mucosa and is expected to 

be attenuated in humans based on the 

strong host range restriction observed in 

non-human primates. To generate these 

MPV/RSV vector vaccine candidates, 

the RSV F ORF was codon optimized, 

placed under the control of MPV 

transcription signals, and inserted at the 

first (rMPV–F1), third (rMPV29 F3), or 

fourth (rMPV–F4) gene position of a 

version of the MPV genome that 

contained a codon-pair optimized L 

polymerase gene. The recovered viruses 

replicated in vitro as efficiently as the 

empty vector, with stable expression of 

RSV F protein. Replication and 

immunogenicity of rMPV–F1 and 

rMPV–F3 were evaluated in rhesus 

macaques following administration by 

the combined intranasal and 

intratracheal routes. Both viruses 

replicated at low levels in the upper and 

lower respiratory tract, maintained 

stable RSV F expression, and induced 

similarly high levels of RSVneutralizing serum antibodies that 

reached peak titers by fourteen (14) days 

post-vaccination. Thus, rMPV provides 

a highly attenuated yet immunogenic 

vector for the expression of RSV F 

protein, with potential application in 

RSV-naı ̈ve and RSV-experienced 

populations. RSV F was expressed in 

the wild-type form, but can readily be 

engineered to be stabilized in the highly 

immunogenic prefusion form, as has 

been done with parainfluenza virus 

vectors. 

The invention relates to live, chimeric 

non-human Mononegavirales vectors 

that allow a cell to express at least one 

protein from at least one human 

pathogen as well as compositions 

comprising the vectors, methods and 

kits for eliciting an immune response in 

a host, and methods of making the 

vectors. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• Viral diagnostics 

• Vaccine research 

Competitive Advantages 

• Ease of manufacture 

• Multivalent live attenuated vaccines 

• B cell and T cell activation 

• Low-cost vaccines 

Development Stage 

• In vivo data assessment (animal) 

Inventors: Shirin Munir (NIAID), 

Linda Brock (NIAID), Ursula Buchholz 

(NIAID), Peter Collins (NIAID). 

Intellectual Property: HHS Reference 

No. E–018–2018/0—U.S. Provisional 

Application No. 62/661,320, filed April 

23, 2018 (expired), PCT Patent 

Application No. PCT/US2019/028771, 

filed April 23, 2019 (expired), 

Taiwanese Patent Application No. 

108114132, filed April 23, 2019 

(pending), Brazilian Patent Application 

No. BR112020021652–6, filed October 

22, 2020 (pending), Australian Patent 

Application No. 2019261570, filed 

October 21, 2020 (pending), Canadian 

Patent Application No. 3097888, filed 

October 20, 2020 (pending), Chinese 

Patent Application No. 201980039372.6, 

filed December 15, 2020 (pending), 

European Patent Application No. 

19729386.3, filed November 13, 2020 

(pending), Indian Patent Application 

No. 20204706248, filed October 23, 

2020, Japanese Patent Application No. 

2020–558967, filed October 22, 2020, 

South Korean Patent Application No. 

2020–7033157, filed November 18, 

2020, and United States Patent 

Application No. 17/049,916, filed 

October 22, 2020. 

Licensing Contact: Peter Soukas, J.D., 

301–496–2644; peter.soukas@nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize for development of a 

vaccine for respiratory or other 

infections. For collaboration 

opportunities, please contact Peter 

Soukas, J.D., 301–496–2644; 

peter.soukas@nih.gov. 

Dated: July 8, 2021. 

Anna V. Ganelina, 

Senior Technology Transfer and Patenting 

Specialist, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2021–14820 Filed 7–12–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Transportation Security Administration 

Revision of Agency Information 

Collection Activity Under OMB Review: 

TSA Customer Comment Tools 

AGENCY: Transportation Security 

Administration, Homeland Security 

(DHS). 

ACTION: 30-Day notice. 

SUMMARY: This notice announces that 

the Transportation Security 

Administration (TSA) has forwarded the 

Information Collection Request (ICR), 

Office of Management and Budget 

(OMB) control number 1652–0030, 

abstracted below to OMB for a revision 

of the currently approved collection 

under the Paperwork Reduction Act 

(PRA). The ICR describes the nature of 

the information collection and its 

expected burden. This collection allows 

customers to provide feedback to TSA 

about their experiences with TSA’s 

processes and procedures, to request 

information or request assistance at the 

TSA checkpoint, and to report security 

threats and vulnerabilities. 

DATES: Send your comments by August 

12, 2021. A comment to OMB is most 

effective if OMB receives it within 30 

days of publication. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under Review—Open for 

Public Comments’’ or by using the find 

function. 

FOR FURTHER INFORMATION CONTACT: 

Christina A. Walsh, TSA PRA Officer, 

Information Technology (IT), TSA–11, 

Transportation Security Administration, 

6595 Springfield Center Drive, 

Springfield, VA 20598–6011; telephone 

(571) 227–2062; email TSAPRA@

dhs.gov. 

SUPPLEMENTARY INFORMATION: TSA 

published a Federal Register notice, 


jbell on DSKJLSW7X2PROD with NOTICES